Mutabilis, the French biopharmaceutical company, has won a grant for €4 million (about US $5.3 million) in European Union (EU) Framework 7 funding as part of a collaborative project to develop new antiretroviral drugs to treat HIV. Mutabilis is coordinating the research. The purpose of the research is to develop a class of antiretrovirals that focuses on the interaction between the virus and host. Researchers involved in the work are the University College London; the Cancer Research Institute, United Kingdom; the Academic Medical Center of the University of Amsterdam; the AIDS Units Clinical Institute of the University of Barcelona; and researchers at the Institute Cochin, France, and the University Hematology Institute of the Saint Louis Hospital in Paris, France. The group can receive up to €6 million (about US $7.9 million) in funding over a three-year time frame.
Date of Publication
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.